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Abstract
Purpose
To develop a tool to evaluate myofascial adhesions objectively in patients with breast cancer
and to investigate its interrater reliability.
Methods
1) Development of the evaluation tool. Literature was searched, experts in the field of myo-
fascial therapy were consulted and pilot testing was performed. 2) Thirty patients (63% had
a mastectomy, 37% breast-conserving surgery and 97% radiotherapy) with myofascial
adhesions were evaluated using the developed tool by 2 independent raters. The Weighted
Kappa (WK) and the intra-class correlation coefficient (ICC) were calculated.
Results
1) The evaluation tool for Myofascial Adhesions in Patients with Breast Cancer (MAP-BC
evaluation tool) consisted of the assessment of myofascial adhesions at 7 locations: axillary
and breast region scars, musculi pectorales region, axilla, frontal chest wall, lateral chest
wall and the inframammary fold. At each location the degree of the myofascial adhesion was
scored at three levels (skin, superficial and deep) on a 4-points scale (between no adhe-
sions and very stiff adhesions). Additionally, a total score (0–9) was calculated, i.e. the sum
of the different levels of each location. 2) Interrater agreement of the different levels sepa-
rately was moderate for the axillary and mastectomy scar (WK 0.62–0.73) and good for the
scar on the breast (WK >0.75). Moderate agreement was reached for almost all levels of the
non-scar locations. Interrater reliability of the total scores was the highest for the scars (ICC
0.82–0.99). At non-scar locations good interrater reliability was reached, except for the infra-
mammary fold (ICC = 0.71).
PLOS ONE | https://doi.org/10.1371/journal.pone.0179116 June 9, 2017 1 / 10
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPENACCESS
Citation: De Groef A, Van Kampen M, Vervloesem
N, De Geyter S, Dieltjens E, Christiaens M-R, et al.
(2017) An evaluation tool for myofascial adhesions
in patients after breast cancer (MAP-BC evaluation
tool): Development and interrater reliability. PLoS
ONE 12(6): e0179116. https://doi.org/10.1371/
journal.pone.0179116
Editor: Gayle E. Woloschak, Northwestern
University Feinberg School of Medicine, UNITED
STATES
Received: February 12, 2016
Accepted: May 25, 2017
Published: June 9, 2017
Copyright: © 2017 De Groef et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: Public sharing of data
is restricted in order to preserve the confidentiality
of the study participants. Data are stored at the
server of the university KU Leuven. Data will be
available upon request to all interested researchers;
readers may contact the corresponding author at
an.degroef@faber.kuleuven.be or the local ethical
committee of the University Hospital Leuven,
Herestraat 49, 3001 Leuven (+32 16 34 86 00 or
ec@uzleuven.be).
Conclusions
The total scores of all locations of the MAP-BC evaluation tool had good to excellent interra-
ter reliability, except for the inframammary fold which only reached moderate reliability.
Introduction
Breast cancer is overall the most frequently diagnosed cancer in women worldwide, with an
estimated 1.7 million new cases in 2012.[1] Due to the adoption of new treatment approaches
survival rate has increased. As a result of different treatment modalities such as axillary and
breast surgery, radiotherapy, hormone therapy and chemotherapy, women can have pain and
upper limb impairments such as impaired range of motion and lymphedema, leading to limi-
tations in activities of daily living and reduced quality of life.[2]
The occurrence or persistence of upper limb impairments after breast cancer treatment can
partially be explained by the presence of myofascial dysfunctions.[3, 4] Myofascial dysfunc-
tions are expressed as myofascial trigger points and adhesions or restrictions of the myofascial
tissues. The latter are impairments of gliding of the myofascial tissues relative to each other.[5–
9] Muscle manipulation during surgery, scar tissue formation, soft tissue adhesions and adap-
tive postures following surgery or fibrosis from radiotherapy can cause myofascial adhesions.
[3, 4, 7, 9]
Currently, several criteria to determine the presence of myofascial trigger points are estab-
lished.[6, 10] Most common applied criteria for myofascial trigger points are 1) palpation of a
taut band, 2) palpation of a tender point on the taut band, 3) local pressure pain and 4) recog-
nizable referred pain.[10] On the other hand, no method or criteria to evaluate myofascial
adhesions exists. Fourie et al determined the presence of myofascial adhesions by palpation for
impaired tissue gliding.[7] However, they did not develop a tool and did not investigate his
assessments on reliability and validity. Ka¨rki et al, investigated the presence of scar tissue tight-
ness by using a questionnaire.[9]
To our knowledge, only one study investigated the effectiveness of myofascial release tech-
niques in breast cancer survivors, however as part of a multidimensional program.[11] In this
study only indirect measurements such as pain and pressure hypersensitivity were used.[11]
However, both in clinical practice and research it is important to verify the presence and
the amount of myofascial adhesions in order to be able to direct treatment and to evaluate
treatment progress. Therefore, a reliable and valid measurement tool is necessary.
The aim of this study was (1) to develop a tool to evaluate myofascial adhesions in breast
cancer survivors and (2) to investigate the interrater reliability of the developed evaluation tool
for Myofascial Adhesions in Patients after Breast Cancer (MAP-BC evaluation tool).
Methods
This observational study was approved by the Ethical Committee of the University Hospitals
Leuven (s54579). All participants gave written informed consent prior to their enrollment in
the study.
1. Development of the MAP-BC evaluation tool
To determine the anatomical locations of myofascial adhesions and how they should be evalu-
ated, two approaches were used. First, literature was searched for studies describing myofascial
Myofascial adhesions in patients with breast cancer
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adhesions and scarring patterns in patients with breast cancer. Secondly, a team of experts was
brought together. This team consisted of three manual therapists: one with one year experience
and two with more than 5 year experience in treatment of myofascial dysfunctions in patients
with breast cancer (ADG, NV and ED). During expert meetings the most relevant anatomical
locations for palpation of myofascial adhesions were determined. Consequently, myofascial
structures at each location were described and categorised in depth levels. Then, a scoring sys-
tem and evaluation method was defined. Finally, pilot testing was performed in 15 patients
with breast cancer.
For the pilot testing, a convenience sample of 15 women who had surgery for breast cancer
were recruited at the Multidisciplinary Breast Centre of the University Hospitals of Leuven
between September 2013 and December 2013. Inclusion criteria were unilateral axillary lymph
node dissection, breast conserving surgery/mastectomy and presence of myofascial adhesions
(determined by clinical examination). Patients with a secondary breast cancer and/or metasta-
sis were excluded. Two therapists of the expert team (ED, ADG) examined the patients inde-
pendently. Experiences, difficulties and findings were discussed afterwards.
2. Reliability of the MAP-BC evaluation tool
The Guidelines for Reporting Reliability and Agreement Studies (GRRAS) were used as a basis
to report this reliability study.[12]
The interrater reliability was independently examined by three raters. Two of them (ADG
and ED) were members of the expert team. The third rater (SDG) was manual therapist as well
with more than 3 years of experience in treatment of myofascial dysfunctions in patients with
breast cancer. Prior to the reliability testing they underwent two types of training. First, a
4-hours training session was held for accuracy of the measurements. During this first training,
all therapists measured and rated together the same patient at the same moment. Second,
training was performed on 20 patients with breast cancer. Inclusion and exclusion criteria for
these training-patients were the same as in the pilot and reliability study. During this second
training, all therapists evaluated the same patient independently. Results were compared and
discussed afterwards.
For the reliability testing, a convenience sample of 30 women who underwent surgery for
breast cancer were recruited at the Multidisciplinary Breast Center of the University Hospitals
of Leuven. Inclusion criteria were unilateral axillary lymph node dissection and breast con-
serving surgery/mastectomy. Patients with a secondary breast cancer and/or metastasis were
excluded. This cohort was measured between January 2014 and December 2014. Two out of
three raters were chosen on the basis of their presence. Measurements took place within a sin-
gle testing session and within this session the order of the different raters was randomly cho-
sen. Both raters were blinded for the results of each other’s measurements. The possibility of a
Hawthorne effect was avoided by making sure the rater was alone in the room during the mea-
surement.[13]
Statistical analysis
For the total score of each anatomical location the Intraclass Correlation Coefficient (ICC) for
single measurements (ICC(2.1)) based on a two-way random effects ANOVA model was used
to determine the interrater reliability. The ICC was calculated using SPSS 22. For the different
myofascial levels separately, the Weighted Kappa coefficient for agreement between 2 raters
was calculated with 95% confidence interval. Additionally, the Absolute Agreement was
reported (with 95% Wilson confidence interval) as the proportion of cases in which both raters
gave exactly the same rating. Analyses of the Weighted Kappa and Absolute Agreement were
Myofascial adhesions in patients with breast cancer
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performed using SAS software (version 9.4 of the SAS System for Windows). An ICC or
Weighted Kappa below 0.50 indicated poor reliability; between 0.51 and 0.75 moderate reli-
ability; between 0.75 and 0.90 good reliability and above 0.90 excellent reliability.[14]
Results
1. Development of the MAP-BC evaluation tool
In the first phase, literature described breast scar tightness in 46% and 29% of patients with
breast cancer at 6 months and 12 months after surgery, respectively.[9] Axillary scar tightness
was described in 46% and 37% patients at 6 months and 12 months after surgery, respectively.
[9] Restricted myofascial tissue gliding was described at the surgical scar (78%), drain sites
(29%), axilla and upper arm (83%), axilla and lateral chest wall (61%), posterior axilla/scapula
(55%), neck (33%) and other surgical sites (39%).[7]
Following anatomical sites were selected from these two studies describing myofascial adhe-
sions. (S1 File):[7, 9] 1) the scar in the axilla (axillary scar), 2) scar on the breast in case of
breast conserving therapy (breast scar) or mastectomy scar in case of mastectomy surgery
(mastectomy scar), 3) muscili (mm) pectorales region (the anterior axillary fold), 4) frontal
chest wall (the sternum), 5) lateral chest wall (the drain site), 6) axilla and 7) inframammary
fold (the place where the breast and the chest meet or used to meet in case of mastectomy).
The area ‘axilla and upper arm’, ‘axilla and lateral chest wall’ and posterior ‘axilla/scapula’
described by Fourie et al[7] were reduced to the axilla itself and the lateral chest wall/drain site
to avoid confusion on the location for palpation. The locations ‘upper arm’, ‘scapula’ and
‘neck’ were not included because these areas seemed less relevant in the field of myofascial
adhesions. According to the experts, these areas should rather be evaluated on the presence of
the axillary web syndrome or myofascial trigger points. Additionally, three locations were
added by the experts based on information retrieved during their clinical activities (i.e. feed-
back of patients on self-perceived myofascial restrictions and restrictions frequently palpated
by the therapists). First, the mm pectorals region was included because this region is often
damaged during breast surgery and by fibrosis after radiation therapy. Second, the frontal
chest wall was included because of the possible adhesions of the cervical fascia in this area after
radiotherapy. Third, the inframammary fold was added. Especially when a mastectomy was
performed, myofascial adhesions could occur in this region.
During the second phase, myofascial structures for each anatomical location were de-
scribed. The different myofascial structures were categorised into 3 depth levels: skin, superfi-
cial myofascial level and deep myofascial level. A schematic overview is given in Fig 1. The
myofascial structures categorised in the superficial and deep level are given in Table 1.
During the last phase, a scoring system and instructions for the therapist were developed
(S1 File). For the scoring, a 4-points ordinal scale was chosen with 0 no adhesions to 3 very
Fig 1. Schematic overview of the different myofascial levels.
https://doi.org/10.1371/journal.pone.0179116.g001
Myofascial adhesions in patients with breast cancer
PLOS ONE | https://doi.org/10.1371/journal.pone.0179116 June 9, 2017 4 / 10
stiff adhesions. Additionally, for each anatomical location a total score between 0 and 9 was
calculated. This was the sum of the scores of the 3 levels.
Characteristics of the patients included in the pilot testing are given in Table 2. Both the
operated and non-operated side were evaluated. With the exception of one item, both raters
agreed on the locations and scoring system of the evaluation tool in its current form. Only for
the frontal chest wall, it was decided to include the skin and superficial level only. It was impos-
sible to discriminate between the superficial and deep myofascial level at this anatomical loca-
tion since the mm intercostales are absent in this region.
2. Reliability of the MAP-BC evaluation tool
Thirty women after axillary lymph node dissection for breast cancer were available for reliability
analysis. For the lateral chest wall, only 28 measurements were available. Patients characteristics
Table 1. The different anatomical locations and the description of the myofascial levelsAnatomical location.
Superficial myofascial level Deep myofascial level
Axillary scar The axilla’ with axillary fascia, fat tissue and glands in the axillary pit.
The axilla is bounded by by mm pectoralis (anterior), insertion of m infraspinatus, mm
teres major and minor and m latissimus dorsi (posterior), m serratus anterior (medial),
m subscapulairs (superior)
mm intercostales externus and internus with
the surrounding fascia intercostalis
Breast scar Subcutaneous fat and glandular tissues of the breast mm pectorals with the surrounding fascia
pectoralis
Mastectomy scar M pectoralis major and surrounding pectoral fascia mm intercostales externus and internus with
the surrounding fascia intercostalis
Mm Pectoralis
region
M pectoralis major and surrounding pectoral fascia mm intercostales externus and internus with
the surrounding fascia intercostalis
Frontal Chest
Wall
M pectoralis major and surrounding pectoral fascia
Lateral Chest
Wall
M serratus anterior and axillary fascia mm intercostales externus and internus with
the surrounding fascia intercostalis
Axilla The axilla’ with axillary fascia, fat tissue and glands in the axillary pit.
The axilla is bounded by by mm pectoralis (anterior), insertion of m infraspinatus, mm
teres major and minor and m latissimus dorsi (posterior), m serratus anterior (medial),
m subscapulairs (superior)
mm intercostales externus and internus with
the surrounding fascia intercostalis
Inframammary
fold
Superficial fascia of the abdominal wall mm intercostales externus and internus with
the surrounding fascia intercostalis
https://doi.org/10.1371/journal.pone.0179116.t001
Table 2. Characteristics of the patients of 1) the pilot study and 2) the reliability study.
Pilot Study (N = 15)
Mean (SD)
Reliability study (N = 30)
Mean (SD)
Age (years) 54.6 (17.4) 52.6 (10.0)
BMI (kg/m2) 26.5 (4.4) 24.6 (3.8)
Time after Radiotherapy (months)* 7 (3–22) 10 (2–12)
Time after surgery (months)* 9 (4–16) 12 (4–14)
Modified Radical Mastectomy 11 (73%) 19 (63%)
Breast Conserving Surgery 4 (27%) 11 (37%)
Chemotherapy 9 (60%) 16 (53%)
Radiotherapy 12 (80%) 29 (97%)
Endocrine therapy 13 (87%) 25 (83%)
Target therapy 3 (20%) 5 (17%)
* interquartile range is given
https://doi.org/10.1371/journal.pone.0179116.t002
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are described in Table 2. In all patients myofascial adhesions were present on at least one ana-
tomical location.
For the total score of each location, the ICC was calculated (Table 3). Interrater reliability of
the total scores of the scars were the highest, reaching good (axillary scar, ICC 0.82) to excellent
reliability (breast scar, ICC 0.99 and mastectomy scar, ICC 0.96). At all other locations, except
for one, good interrater reliability was reached (ICC 0.76–0.87). The ICC for the inframam-
mary fold was the lowest, reaching only moderate reliability (ICC 0.71).
For the different depth levels at each location separately, the Weighted Kappa and Absolute
Agreement were calculated. Fig 2 gives an overview of the interrater agreement. For both the
axillary and mastectomy scar, moderate agreement was found for all levels (Weighted Kappa
0.62–0.73). The skin had the best agreement. For all levels of the breast scar at least good agree-
ment was found (Weighted Kappa > 0.75). For all scars absolute agreement was higher than
Table 3. Interrater reliability (ICC) between two raters for the total score of myofascial adhesions. For each anatomical location the prevalence rate of
myofascial adhesions is given.
Location Rater 1
Median (IQR)
Rater 2
Median (IQR)
ICC (95% CI) Number (%) of patients with adhesions
Axillary Scar
(N = 30)
4 (2.00–6.00) 4 (3.00–6.00) 0.82 (0.65–0.91) 30 (100%)
Breast Scar
(N = 11)
0 (0.00–4.25) 0 (0.00–5.00) 0.99 (0.99–0.99) 11 (100%)
Mastectomy Scar (N = 19) 3 (0.00–6.00) 3 (0.00–6.00) 0.96 (0.92–0.98) 19 (100%)
Mm pectorales region (N = 30) 3 (0.75–5.00) 3 (1.00–4.25) 0.87 (0.73–0.93) 23 (77%)
Frontal Chest Wall (N = 28) 2 (0.00–3.25) 1 (0.00–2.25) 0.76 (0.55–0.88) 19 (68%)
Lateral Chest Wall (N = 30) 3 (1.00–4.25) 3 (2.00–4.00) 0.80 (0.62–0.90) 27 (90%)
Axilla
(N = 30)
3 (1.00–5.00) 3.5 (2.00–3.50) 0.85 (0.71–0.93) 26 (87%)
Inframammary fold (N = 20) 3 (0.00–3.00) 3 (1.75–3.25) 0.71 (0.48–0.85) 21 (70%)
IQR = Interquartile range; ICC = Intraclass correlation coefficient
https://doi.org/10.1371/journal.pone.0179116.t003
Fig 2. Overview of the Weighted Kappa and Absolute Agreement of the different myofascial levels.
The Weighted Kappa (lines), Absolute Agreement (numbers) and their 95% CI for the agreement between
two raters on the scoring of the degree of myofascial adhesions for different anatomical locations is given. Per
anatomical location the different myofascial levels are given from top to bottom: skin (dotted line)–superficial
(full line)–deep (dashed line).
https://doi.org/10.1371/journal.pone.0179116.g002
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73%, except for the deep level of the axillary and breast scar. For the levels of the other non-
scar locations moderate interrater agreement was reached, except for five levels. The deep level
of the lateral chest and the skin of the axilla reached good agreement. Interrater agreement of
the skin and deep level of the inframammary fold and superficial level of the lateral chest
reached only poor agreement. In general, the levels of the inframammary fold scored the low-
est (Weighted Kappa 0.41–0.53). Absolute agreement between two raters for non-scar loca-
tions ranged between 60% and 86%.
Discussion
In this study a tool was developed to evaluate myofascial adhesions objectively in patients with
breast cancer: the MAP-BC evaluation tool. Additionally, its interrater reliability was investi-
gated. For all 7 locations the total score reached good to excellent interrater reliability, except
for the inframammary fold which only reached moderate interrater reliability. Interrater
agreement of almost all levels at the different anatomical locations was moderate. Interrater
agreement of the inframammary fold was the lowest and interrater agreement of the scars
(axilla, breast/mastectomy) was the highest. Absolute agreement between two raters ranged
between 60 and 91%, with again the best agreement for the evaluation of the scars.
The interrater reliability of the evaluation of the scars (axilla, breast/mastectomy) was the
highest. This may be explained by two reasons. First, these locations were well defined so both
raters were more likely to examine exactly the same site. Second, the different myofascial levels
were easier to distinguish compared to other locations. At the skin level the linear scar was pal-
pable and the degree of adhesion at this level was determined by the ability of moving the scar
itself relatively to the underlying soft tissues. The superficial and deep level of the breast scar
reached almost excellent agreement because the superficial myofascial tissues under the breast
scar, i.e. fat and glandular tissue, are easy to distinguish from the deep myofascial level. At the
mm pectorales region determination of the exact location and distinction of the different levels
were expected to be feasible as well. However, interrater agreement values were lower com-
pared to the scars. Possible explanation might be the presence of post-radiotherapy edema or
the presence of fat tissue in this region.[15] The same explanations could also be applied for
lower interrater agreement values of the superficial level of the lateral chest wall. At this loca-
tion fat tissue and/or an excess of skin are very common, which made the distinction of the dif-
ferent levels harder. Myofascial adhesions might be present at the lateral chest wall because of
the inserted drain after surgery. In the first place, the scar of the drain insertion point was
intended to be evaluated. Secondly, the adhesion caused by the drain itself that runs along the
chest wall had to be evaluated. The combination of both types of adhesions might have resulted
in lower interrater agreement values. Therefore, it was possibly better to score the scar of the
insertion point of the drain and the adhesions along the lateral chest wall separately. Interrater
agreement of the axilla was moderate, except for the skin level. This may be due to difficult dis-
tinction of the superficial and deep myofascial level. The superficial level consists of a package
of fat tissue and glandular tissue that should be movable in the axillar pit in all directions.
However, after surgery and/or radiotherapy swelling and fibrosis may occur in this region
making this package of soft tissues itself harder. Further the presence of the axillary web syn-
drome may compromise the palpation for adhesions.[16] It may be possible that the scoring of
the adhesions was compromised or confused with the hardness of the soft tissues itself. There-
fore, it may be useful to score the hardness itself of the soft tissues at the superficial level and
the degree of adhesions with the underlying tissues separately. Additionally, the remark should
be made that, especially in the axillar region, the starting position of the arm (i.e. 90˚ abduc-
tion) is very important. Lastly, interrater agreement of the inframammary fold was the lowest.
Myofascial adhesions in patients with breast cancer
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Adhesions in this region can be caused by two things. First, during the mastectomy procedure
the glandular tissue is removed and the skin is folded towards the thorax. Second, a drain may be
inserted in this region after surgery. The inframammary fold region is again a wide region and
determination of the exact location for palpation might not have been clear, certainly in case of
mastectomy. In general, the inframammary fold is located at the 6th rib, it might have been useful
to specify this in the instructions. Likewise at the frontal chest wall, the superficial and deep level
might have been difficult to distinguish. Scoring these two levels together at the inframammary
fold might have resulted in higher interrater agreement values as well.
In clinical practice, we recommend to use the total scores of the different locations of the
MAP-BC evaluation tool. The evaluation takes about 15–20 minutes. The total scores can be
used to identify the presence of myofascial adhesions and to direct treatment. Additionally, these
scores can be used to evaluate the effect of myofascial therapy or other physical therapy modali-
ties on the myofascial adhesions in patients with breast cancer in a direct way. In line with the
evaluation of the frontal chest wall, we recommend to score the superficial and deep level of the
inframammary fold together, however interrater agreement was not investigated. The presence
of the axillary web syndrome should be registered separately. Before using the MAP-BC evalua-
tion tool, clinical experience in myofascial therapy and a training period is recommended. How-
ever, the exact amount of training needed to obtain reliable results should be further explored.
This study has several strengths. First, the measurements were performed in ‘the field’ with
the same disadvantages as when performed for clinical purposes, as time-limitations and phys-
ical limitations of the patient. Second, the developed tool is a quantitative measurement.
Third, the development process of the tool was well established and based on literature, experts
and patients experiences.
Some limitations should be mentioned as well. First, in total 30 patients were included but
for the mastectomy and breast scar smaller groups of 19 and 11 patients, respectively, were
available. Second, only interrater reliability was investigated. Intrarater reliability was not
tested since we assumed that intrarater reliability will be as good as or even better than interra-
ter reliability.[17]
The Cosmin Checklist distinguishes three domains in assessing the quality of a measure-
ment instrument, i.e. reliability, validity and responsiveness.[18] The present study focused
on interrater reliability of the MAP-BC evaluation tool in breast cancer survivors. Reliability
should be further explored in other populations with myofascial adhesions and other scar
areas. Further research should explore the validity of the MAP-BC evaluation tool; more
specific, content validity, construct validity and criterion validity. In a further stage, respon-
siveness of the evaluation tool to myofascial therapy should be tested in larger samples. Addi-
tionally, the MAP-BC evaluation tool can be used to get more insight in the contribution of
myofascial adhesions to pain and upper limb problems in patients with breast cancer. The rela-
tionship between myofascial adhesions and different treatment modalities on the one hand
and pain and upper limb problems on the other hand should be explored.
In this study the MAP-BC evaluation tool was developed to evaluate myofascial adhesions
quantitatively in patients with breast cancer. The total scores of each location had good to
excellent interrater reliability, except for the inframammary fold. Almost all myofascial levels
at each location reached moderate agreement.
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